BioTuesdays

Category - Developments

Dipexium Pharmaceuticals
Developments

Dipexium reaches 75% enrolment in Phase 3 trials

Dipexium Pharmaceuticals’ (NASDAQ:DPRX) OneStep-1 and OneStep-2 pivotal Phase 3 clinical trials have reached the 75% enrollment milestone in total, with each study having enrolled nearly the same number of patients...

February 4, 2016
Venaxis
Developments

Venaxis to merge with Strand Life Sciences

Venaxis (NASDAQ:APPY) has entered into a series of agreements for a transaction with Strand Life Sciences Private Limited and its shareholders. Strand is a privately-held, global genomics and bioinformatics company...

January 27, 2016
EyeGate Pharmaceuticals
Developments

EyeGate starts confirmatory Phase 3 trial in AU

EyeGate Pharmaceuticals (NASDAQ:EYEG) has enrolled the first patient in a confirmatory Phase 3 clinical trial of its EGP-437 combination lead product in patients with non-infectious anterior uveitis, an inflammation of...

January 19, 2016
novadaq
Developments

Novadaq Q4 revenue to jump about 54%

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has released preliminary unaudited revenue for the fourth quarter of 2015 of approximately $20-million, reflecting increases of about 54% from $13-million in the 2014 fourth...

January 12, 2016